Oxford Biodynamics PLC
LSE:OBD

Watchlist Manager
Oxford Biodynamics PLC Logo
Oxford Biodynamics PLC
LSE:OBD
Watchlist
Price: 0.28 GBX 1.82% Market Closed
Market Cap: £12m

Net Margin

-1 018.5%
Current
Improving
by 810.7%
vs 3-y average of -1 829.2%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 018.5%
=
Net Income
£-11.2m
/
Revenue
£1.1m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 018.5%
=
Net Income
GBX-11.2m
/
Revenue
£1.1m

Peer Comparison

Country Company Market Cap Net
Margin
UK
Oxford Biodynamics PLC
LSE:OBD
12m GBP
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.2T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
223.2B USD
Loading...
US
Danaher Corp
NYSE:DHR
154.9B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
82.4T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
37.3B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
40.3B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
274.9B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
37.4B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
28.2B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
18.6B EUR
Loading...

Market Distribution

Lower than 99% of companies in United Kingdom
Percentile
1st
Based on 3 670 companies
1st percentile
-1 018.5%
Low
-188 120% — 0%
Typical Range
0% — 0.1%
High
0.1% — 10 443.9%
Distribution Statistics
United Kingdom
Min -188 120%
30th Percentile 0%
Median 0%
70th Percentile 0.1%
Max 10 443.9%

Oxford Biodynamics PLC
Glance View

Oxford BioDynamics Plc is a biotechnology company, which engages in the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. The firm is engaged in advancing personalized healthcare by developing and commercializing medicine tests for life-changing diseases. The company has developed a three dimensional (3D) genomic biomarker platform, EpiSwitch, which builds molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a range of indications. The platform discovers, evaluates, validates and monitors of biomarkers known as chromosome conformation signatures (CCSs). CCSs provides a compelling, stable framework from which changes in the regulation of a genome can be analyzed, long before the results of these epigenetic changes manifest themselves as obvious abnormalities. EpiSwitch supports precision medicine initiatives, including prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring.

OBD Intrinsic Value
0.24 GBX
Overvaluation 15%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-1 018.5%
=
Net Income
£-11.2m
/
Revenue
£1.1m
What is Oxford Biodynamics PLC's current Net Margin?

The current Net Margin for Oxford Biodynamics PLC is -1 018.5%, which is above its 3-year median of -1 829.2%.

How has Net Margin changed over time?

Over the last 3 years, Oxford Biodynamics PLC’s Net Margin has increased from -4 357.1% to -1 018.5%. During this period, it reached a low of -4 357.1% on Aug 30, 2022 and a high of -1 018.5% on Oct 30, 2025.

Back to Top